May 6, 2026
300 patients randomised. And every single one has a story.
But behind that number is something no dataset fully captures.
A patient who travelled two hours to reach the clinical site. A surgeon who completed the protocol at 11pm. Ethics committees across 7 countries who believed this was worth doing.
Why this milestone matters
Liver cancer and colorectal liver metastases (CRLM) are two of the most challenging oncological conditions in Europe. Liver resection remains the only potentially curative option for many of these patients — yet even after successful surgery, tumour recurrence rates remain high.
The LIVERATION trial is investigating whether the COOLINGBIS device, which applies radiofrequency ablation to the surgical margin after liver resection, can reduce local recurrence and improve patient outcomes.
Thank you to the entire consortium: IMIM, ECRIN, Vecmedical, SACSIS, UOI, SHINE 2Europe, FAD and ELPA. And above all, thank you to every patient who placed their trust in us.
Science doesn’t move forward on its own. It moves forward with people.
For more information visit liveration.eu